Featured XIENCE Short DAPT Trials
“Two really exciting studies but much more important is what we're doing for the patients.”
ROXANA MEHRAN, MD, GLOBAL PRINCIPAL INVESTIGATOR
“We really are in a dilemma in balancing the risk of ischemic events that are associated with PCI...compared to their bleeding risk...with prolonged DAPT”
— ROXANA MEHRAN, MD, GLOBAL PRINCIPAL INVESTIGATOR
Abbott has established the XIENCE Short DAPT program of clinical trials, which focuses on high risk bleeding patients. Shortening DAPT (Dual AntiPlatelet Therapy) duration may be particularly important for patients at higher risk of bleeding, e.g., older patients, patients taking anticoagulants, and patients with anemia or renal disease.
The studies in the XIENCE Short DAPT program are:
Dr. Mehran is global principal investigator of the XIENCE 90 trial. The principal investigator of the XIENCE 28 study is Marco Valgimigli, MD.
Currently physicians have no clear guidance when weighing their patients’ needs and risk factors—their need for DAPT to reduce ischemic complications after percutaneous coronary intervention (PCI) and, for many patients, their bleeding risk while on prolonged DAPT.
“We have a lot of patients in whom DAPT cannot be longer than 1 [month] and we need to provide some answers to them.”
— MARCO VALGIMIGLI, MD
Discover more about Xience
AP2944533-WBO Rev. B